Company: INDP
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0001493152-25-010136
Chunk: 315

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 1B
Chunk 315
---
 and supervises
our retained provider of IT services and external cybersecurity consultants. Our Chief Operating Officer has experience supervising and
managing company security and privacy departments.

Our
management team supervises efforts to prevent, detect, mitigate, and remediate cybersecurity risks and incidents through various means,
which may include briefings from external security personnel; threat intelligence and other information obtained from governmental, public
or private sources, including external consultants engaged by us; and alerts and reports produced by security tools deployed in the IT
environment.

Item
2. Properties

Our
principal executive offices are located at 3 Columbus Circle, 15th Floor, New York, NY. In addition, we lease approximately 2,000 square
feet of office space in San Diego, California under a lease agreement that was amended on April 19, 2023 and will expire on October 31,
2025. We believe that our facilities are sufficient to meet our current needs and that suitable
additional space will be available as and when needed.

62

Item
3. Legal Proceedings

From
time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation
is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business.

As
of March 12, 2025, there are no pending material legal proceedings, and we are currently not aware of any legal proceedings or claims
against us or our property that we believe will have any significant effect on our business, financial position or operating results.
None of our officers or directors is a party against us in any legal proceeding.

Item
4. Mine Safety Disclosures.

Not
applicable.

PART
II

Item
5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market
Information

Our
common stock is listed on the Nasdaq Capital Market under the name “Indaptus Therapeutics, Inc.” and ticker symbol “INDP”.

Holders

As
of March 12, 2025, we had 22 record holders of our common stock. This number does not include the number of persons whose shares are
in nominee or in “street name” accounts through brokers.

Dividend
Policy

We
have never declared or paid cash dividends to our shareholders, and we do not intend to pay cash dividends in the foreseeable future.
We intend to reinvest any earnings in